Komori
Share Issuance and Disposal4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation

Payment has been completed for the disposal of 32,700 treasury shares as restricted stock compensation, as resolved on 15 July 2025.

Worth reading
26Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
32700
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Disposal of treasury shares as restricted stock compensation

Who receives how much32,700Shares

当社普通株式 32,700株(自己株式)

1 of the Company's executive officers1,500 shares
9 directors of the Company's subsidiaries20,400 shares
7 executive officers of the Company's subsidiaries10,800 shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

1株につき2,367円
Total issue value77,400,900Yen
Categories and Number of Persons Covered
Category The Company's executive officers / Number of Employees 1 / Number of allocated shares 1,500 shares, Category Directors of subsidiaries of the Company / Number of Employees 9 / Number of allocated shares 20,400 shares, Category Executive officers of the Company's subsidiaries / Number of Employees 7 / Number of allocated shares 10,800 shares
Payment date
2025年8月13日
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDisposal of treasury shares as restricted stock compensation
Number of shares to be issued or disposed of当社普通株式 32,700株(自己株式)
Issue price and disposal price1株につき2,367円
Total issue value77,400,900円
Payment date2025年8月13日
Intended allotteeName 1 of the Company's executive officers / Number of Shares 1,500 shares, Name 9 directors of the Company's subsidiaries / Number of Shares 20,400 shares, Name 7 executive officers of the Company's subsidiaries / Number of Shares 10,800 shares
Categories and Number of Persons CoveredCategory The Company's executive officers / Number of Employees 1 / Number of allocated shares 1,500 shares, Category Directors of subsidiaries of the Company / Number of Employees 9 / Number of allocated shares 20,400 shares, Category Executive officers of the Company's subsidiaries / Number of Employees 7 / Number of allocated shares 10,800 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The shares were disposed of as restricted stock compensation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the Disposal of Treasury Shares as Restricted Stock-Based Compensation | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori